dm 4

DM4 (Ravtansine) can be used in the preparation of antibody drug conjugate and it is an antitubulin agent. It can inhibit cell division.

DM4-SMe is a cytotoxic part of antibody-drug conjugates (ADCs) and a metabolite of antibody-maytansin conjugates (AMCs) and tubulin inhibitors, which can also be stabilized by disulfide bonds or thioether The bond binds to the antibody. The IC50 of DM4-SM

Maytansinoid DM4, a thiol-containing maytansine derivative, is a highly potent cytotoxic moiety utilized in ADC applications.

DM4-SMCC, a non-cleavable drug-linker conjugate for antibody-drug conjugates (ADC), leverages the antitumor efficacy of DM4 (an antitubulin agent) through attachment with the SMCC linker, exhibiting antitumor activity[1].

DM4-SPDP, a drug-linker conjugate, integrates the antitubulin agent DM4 with the linker SMCC, facilitating the creation of antibody drug conjugates[1]. Additionally, SPDP serves as a short-chain crosslinker enabling amine-to-sulfhydryl conjugation, leveraging NHS-ester and pyridyldithiol groups to establish cleavable (reducible) disulfide bonds with cysteine sulfhydryls[2][3].

SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, employing the maytansine-based payload DM4 (a tubulin inhibitor) connected through a SPDB linker. This compound demonstrates significant anti-tumor efficacy.

DBA-DM4 is a drug-linker conjugate used in antibody-drug conjugate (ADC) synthesis, combining the tubulin inhibitor DM1 with the SPDP linker [1].

Sulfo-SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugates (ADCs) that employs the maytansine-based payload (DM4, an antitubulin agent) connected through the sulfo-SPDB linker.

Sulfo-PDBA-DM4 is a drug-linker conjugate for antibody-drug conjugate (ADC) applications, combining the potent tubulin inhibitor DM4 with the gluthatione-cleavable linker Sulfo-PDBA. This configuration harnesses DM4's cytotoxic potential through Sulfo-PDBA's targeted delivery mechanism.

Lys-Nε-SPDB-DM4 is a drug-linker conjugate that integrates the tubulin inhibitor DM4 with the linker Lys-Nε-SPDB, enabling the formation of an antibody-drug conjugate (ADC).

S-Me-DM4 is an intracellular enzyme S-methylated metabolite of DM4, a maytansinoid with microtubule-depolymerizing properties and potent cytotoxicity, employed as an Antibody-Drug Conjugate (ADC) cytotoxin [1].

DM4-D6 is a deuterated form of DM4, an antimicrotubule agent that inhibits cell division. DM4 (T15141-GMP) is utilized in the preparation of antibody-drug conjugates (ADCs).

Anti-CCL2 (Carlumab)-SPDB-DM4 is an antibody-drug conjugate (ADC) composed of the human-derived anti-CCL2 (chemokine ligand 2) antibody Carlumab, linked to the microtubule inhibitor DM4 via the SPDB linker. The toxic component and linker of the ADC are sulfo-SPDB-DM4. This compound is utilized in cancer research.

Anti-SLC34A2 (Lifastuzumab)-SPDB-DM4 is an antibody-drug conjugate (ADC) composed of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody, Lifastuzumab, linked via SPDB to the tubulin inhibitor DM4. The toxic component and linker of this ADC is sulfo-SPDB-DM4. This compound can be utilized for cancer research.

Human IgG1-sulfo-SPDB-DM4, ADC Control is an ADC control reagent that can be used as an isotype or negative control for IgG1-sulfo-SPDB-DM4-based ADC studies.

ADC Control Human IgG1-DM4 serves as the isotype control for ADC Human IgG1-DM4. It comprises an antibody portion identified as HumanIgG1kappa, Isotype Control, whereas the toxic molecule and linker components are SPDB-DM4.

Tusamitamab ravtansine (SAR-408701) is a DM4-linked anti-CEACAM5 antibody-drug conjugate (ADC) comprising a humanized monoclonal antibody targeting carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5) conjugated to a cytotoxic maytansinoid, selectively engaging CEACAM5-positive tumor cells [1].

Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) that consists of a murine-human chimeric form based on B-B4, which specifically targets CD138, linked via a disulfide bond to the maytansinoid drug DM4. It exhibits antitumor activity.

DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate that combines the microtubulin inhibitor DM1 (mertansine), an antibody-conjugatable maytansinoid designed to reduce systemic toxicity and improve tumor-specific delivery, with the linker DBCO-PEG4-Ahx, for developing antibody drug conjugates (ADCs).

DM1-(PEG)4-DBCO is a drug-linker conjugate that combines the potent microtubulin inhibitor mertansine (DM1) with the DBCO-PEG4-Ahx linker for developing antibody-drug conjugates (ADCs). This conjugation aims to mitigate systemic toxicity associated with maytansine while improving tumor-specific delivery, leveraging DM1's ability as an antibody-conjugatable maytansinoid.

Mal-PEG4-VC-PAB-DMEA-duocarmycin-DM is a thiol-reactive Drug-linker. Duocarmycin DM is a DNA alkylating agent that can be used as a toxin for ADC conjugates and is employed in the synthesis of antibody-drug conjugates (ADCs).

DBCO-PEG4-VC-PAB-Ahx-DM1 is a click-reactive Drug-linker that contains a DBCO group and can undergo strain-promoted acetylene-nitride cycloaddition reaction (SPAAC) with molecules containing Azide groups. DM1 is a microtubule protein inhibitor. DBCO-PEG4-VC-PAB-Ahx-DM1 can be used in the synthesis of antibody-drug conjugates (ADCs).

MA-PEG4-VC-PAB-DMEA-duocarmycin DM TFA is a component of antibody-drug conjugates (ADC), specifically a drug-linker conjugate for ADC. It comprises the DNA minor groove alkylating agent Duocarmycin DM linked via the linker MA-PEG4-vc-PAB-DMEA.

MA-PEG4-VC-PAB-DMEA-Duocarmycin DM is a drug-linker conjugate for ADC, utilizing the anticancer antibiotic Duocarmycin DM, linked via MA-PEG4-VC-PAB-DMEA [1] [2].